SCHEMBL7567200

SCHEMBL7567200

O=C(NN=Cc1ccccc1)c1[nH]c2ccccc2c1-c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.75
LMNA P02545 6/20 0.75
ALDH1A1 P00352 7/20 0.66
MEN1 O00255 6/20 0.66
KMT2A Q03164 6/20 0.66
KDM4E B2RXH2 5/20 0.66
PAX8 Q06710 2/20 0.66
SMN1; SMN2 Q16637 4/20 0.61
HPGD P15428 3/20 0.61
RAB9A P51151 3/20 0.61
TUBB4A P04350 2/20 0.61
TUBB P07437 2/20 0.61
TUBA3C P0DPH7 2/20 0.61
TUBA1B P68363 2/20 0.61
TUBA4A P68366 2/20 0.61
TUBB4B P68371 2/20 0.61
TUBB3 Q13509 2/20 0.61
TUBB2A Q13885 2/20 0.61
TUBB8 Q3ZCM7 2/20 0.61
TUBA3E Q6PEY2 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7567198 1.00 MAPT (0.75) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7530988 0.93 ALDH1A1 (0.77) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7560935 0.93 ALDH1A1 (0.77) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7560031 0.92 MAPT (0.65) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7673218 0.92 MAPT (0.65) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7673252 0.92 TUBB4A (0.70) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7530637 0.92 TUBB4A (0.70) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7559751 0.92 MAPT (0.78) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7673213 0.92 MAPT (0.65) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL7560034 0.92 MAPT (0.65) MAPTLMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885LMNA 4535/4885ALDH1A1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.